There were 28.65 and 16.34 cases of HCC per 1,000 person-years from 2009 to 2013 in the non-DPP-4 inhibitor group and DPP-4 inhibitor group, respectively (Table 2). This evidence concerns the gene DPP4 and hepatocellular carcinoma.